CommercialCoverageMedium impact
06.02.53, Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Independence Blue Cross·Urology, Oncology, Internal Medicine +1 more·Medical Policy
Effective date
Jan 27, 2025
We identified it
Jun 19, 2026
Summary
A new commercial policy (06.02.53) covering protein biomarkers for prostate cancer diagnosis and risk assessment takes effect January 27, 2025. This establishes coverage criteria and billing guidelines for protein biomarker testing used in prostate cancer evaluation.
Action Required
By January 27, 2025: Billing team must review the full policy details at the provided URL to understand coverage criteria for protein biomarker testing in prostate cancer cases. Update billing protocols and prior authorization requirements as specified in the complete policy document.